11 results
10-K
2021 FY
ABOS
Acumen Pharmaceuticals Inc
28 Mar 22
Annual report
4:51pm
available and when appropriate. We rely upon know-how and continuing technological innovation to develop and maintain our competitive position. We seek … , includes a subtitle called the Biologics Price Competition and Innovation Act, or BPCIA, which created an abbreviated approval pathway for biological
8-K
EX-99.1
ABOS
Acumen Pharmaceuticals Inc
7 Oct 21
Regulation FD Disclosure
8:23am
of scientific innovation that is being applied to Alzheimer’s research. We believe ACU193 has distinct potential to address the continued unmet medical
10-Q
mb6k xxshj
16 Aug 21
Quarterly report
4:51pm
424B4
sq8 629zi
2 Jul 21
Prospectus supplement with pricing info
4:09pm
S-1/A
152uhjbc
24 Jun 21
IPO registration (amended)
8:17am
S-1
bogmp2ft73wuatsvm ts
9 Jun 21
IPO registration
5:02pm
DRS/A
39hm1nb7mf hxtqdbzft
14 May 21
Draft registration statement (amended)
12:00am
DRS
5wh4 ocrbsb3bp9
12 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next